Novartis AG
OTC:NVSEF

Watchlist Manager
Novartis AG Logo
Novartis AG
OTC:NVSEF
Watchlist
Price: 152 USD -1.84%
Market Cap: $312.5B

Operating Margin

42%
Current
Improving
by 10.9%
vs 3-y average of 31.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
42%
=
Operating Income
$18.6B
/
Revenue
$56B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
42%
=
Operating Income
$18.6B
/
Revenue
$56B

Peer Comparison

Country Company Market Cap Operating
Margin
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Johnson & Johnson
NYSE:JNJ
547B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
265.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.3B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
112B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.4B USD
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.8B USD
Loading...

Market Distribution

Higher than 92% of companies in Switzerland
Percentile
92st
Based on 1 083 companies
92st percentile
42%
Low
-62 472.2% — 3.5%
Typical Range
3.5% — 16.5%
High
16.5% — 91.2%
Distribution Statistics
Switzerland
Min -62 472.2%
30th Percentile 3.5%
Median 10.3%
70th Percentile 16.5%
Max 91.2%

Novartis AG
Glance View

Nestled in the heart of Europe's pharmaceutical landscape, Novartis AG has firmly etched its presence as a beacon of innovation and scientific prowess. This Swiss multinational behemoth, headquartered in Basel, operates at the confluence of research-driven development and cutting-edge technology. At its core, Novartis is devoted to discovering novel therapeutics and delivering them to patients across the globe. The company’s operations span various segments, with Pharmaceuticals and Oncology standing as the pillars of its revenue model. Through these divisions, Novartis vigorously pursues advancements in the treatment of diseases, focusing on areas such as cardiovascular, immunology, neuroscience, respiratory, and oncology. The innovative medicines they develop emerge from robust pipelines bolstered by strategic investments in research and development, propelling them to the forefront of healthcare innovation. Moreover, Novartis leverages a synergy between its Sandoz division, which is known for a strong generics and biosimilars portfolio, and its advanced therapeutic areas in Pharmaceuticals. This duality not only makes the company versatile but also resilient in the face of market volatilities. Unlike many pharmaceutical giants, Novartis prioritizes a hybrid approach by combining cutting-edge biotechnology with a stronghold in cost-effective generics. This model allows Novartis to cater to both the high-margin, innovation-driven segments and the volume-based, lower-margin arenas. Ultimately, their strategic focus is not just on creating the next blockbuster drug but on improving access to healthcare solutions globally, thereby reinforcing its revenue engine while delivering on its mission to reimagine medicine.

NVSEF Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
42%
=
Operating Income
$18.6B
/
Revenue
$56B
What is Novartis AG's current Operating Margin?

The current Operating Margin for Novartis AG is 42%, which is above its 3-year median of 31.1%.

How has Operating Margin changed over time?

Over the last 3 years, Novartis AG’s Operating Margin has increased from 23.1% to 42%. During this period, it reached a low of 21.3% on Sep 30, 2023 and a high of 42.2% on Jun 30, 2025.

Back to Top